Építés alatt – nem éles oldal
Belépés
Résztvevőt keres2/3. fázis

Adaptative, multicenter, randomized, double-blind, parallel-group, placebo controlled, clinical trial, on the efficacy and tolerability of different escalating doses of intra-articular clodronate in patients with painful knee osteoarthritis

A legfontosabb adatok

Ki végzi
Spa Societa Prodotti Antibiotici S.p.A.
Hol
Olaszország14 helyszín, 1 országbanVálassz országot a helyszínekhez
Állapot
Toboroz
Fázis
2/3. fázis
Résztvevők
278 fő, tervezett
Kezdés
2023. okt. 12.
Tervezett befejezés
2026. febr. 1.
A vizsgálat típusa
Beavatkozással járó
A regiszteradat frissítve
2026. április 29.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults aged 50 to 75 with painful knee osteoarthritis (wear-and-tear arthritis). It tests clodronate injected into the knee against a placebo.

Életkor
50 to 75 years at signing of the consent form.
Nem
Women and men.
A betegség stádiuma
Knee osteoarthritis confirmed by X-ray, Kellgren-Lawrence score 2 to 3 in the main knee joint. Knee pain for at least 6 months, with a pain score (VAS) between 40 and 80 mm.
Korábbi kezelés
No knee surgery or knee replacement ever. No denosumab or systemic bisphosphonates in the last 12 months. No knee injections, such as corticosteroids or hyaluronic acid, in the last 3 months. No NSAIDs in the week before the start. Other drug pauses apply too.
Biomarker vagy leletérték
Women who can become pregnant need a negative pregnancy test before each treatment and at Week 4.

A részvétel fő kizáró okai

  • BMI > 35 kg/m2.
  • Jaw bone death (osteonecrosis) in the last 24 months, or a risk of it.
  • Allergy to the study drug, other bisphosphonates or paracetamol.
  • Poor blood, kidney or liver test results, for example eGFR < 60 mL/min.
  • Pregnant or breastfeeding women, or women planning a pregnancy.

A regiszter feltételei, szó szerint

Mind a 27 feltétel megnézéseKevesebb

Ki vehet részt

  • Female and male patients aged 50 up to 75 years at the signature of informed consent form (ICF)
  • Diagnosis of knee OA according to the American College of Rheumatology, confirmed by Rx during the screening (a Rx performed in the last three (3) months before Screening Visit is accepted)
  • Kellgren-Lawrence radiographic score between 2 and 3 degrees in the tibiofemoral joint
  • Symptomatic knee OA (pain) since at least 6 months with a knee pain (VAS) ranging between 40 and 80 mm at Screening visit (the figure should be confirmed at Baseline)
  • Female patients of childbearing potential must have a negative pregnancy test before each treatment and during the Visit 5 – Week 4 and they must use adequate methods of contraception throughout the course of the study
  • A signed ICF by the patient after exhaustive study discussion with the investigators

Ki nem vehet részt

  • Any treatment with denosumab in the 12 months before Baseline
  • Any treatment with paracetamol in the twelve (12) hours before Baseline
  • Any knee surgery in the past or knee arthroplasty
  • Any diagnostic or surgical arthroscopy of the knee in the six (6) months before Baseline
  • Any jaw osteonecrosis in the last twenty-four (24) months before Baseline or at a risk of jaw osteonecrosis
  • Any participation in a clinical study in which the last administration of the investigational medicinal product was within two (2) weeks before consenting to study participation (i.e. signing ICF)
  • Any treatment with IA drugs in the last three (3) month before Day 0- Baseline (including any formulation of corticosteroids, or hyaluronic acid injections)
  • Corticosteroid use by any systemic route, and hyaluronic acid injections or in-tra-articular corticosteroids for any other joint in the previous month will be not permitted
  • Any treatment with systemic non-steroidal anti-inflammatory drugs (NSAIDs) in the week before Baseline, or any steroid anti-inflammatory drugs and chon-droprotective drugs in the thirty (30) days before Baseline
  • Any treatment with systemic bisphosphonates in the last twelve (12) months before Baseline
  • Any treatment with glucosamine or chondroitin sulfate, diacerein and matrix metalloproteinase (MMP) inhibitors in the 4 weeks before Baseline
  • Any known hypersensitivity to the drug in the study and to its excipients or other bisphosphonates, and any hypersensitivity to paracetamol (rescue drug)
  • Any positive or suspected history of alcoholism or drug use
  • Joint instability due to other reasons than knee OA, such as f.i. algo dystrophic syndrome, either partial or complete rupture of internal / externals ligaments, kneecap instability, etc
  • Clinically significant (i.e.) gastrointestinal, renal, hepatic, pulmonary, cardiovascular or neurological disease that could interfere with the outcome of the study or the patient’s ability to comply with study requirements
  • Other musculoskeletal disorders related to the target knee
  • Inadequate organ function defined by the following laboratory parameters: Absolute Neutrophil Count (ANC) < 1500/^l ; Haemoglobin (Hb) < 9 g/dl (< Hb 5.6 mmol/L) ; Platelet Count < 100.000/^l ; Serum Creatinine > 1.5 x ULN or eGFR < 60 mL/min (as per Cockroft-Gault formula) ; ALT or AST > 1.5 x ULN ; Serum Total Bilirubin > 1.5 x ULN
  • BMI > 35 kg/m2 (Class II obesity)
  • Pregnant or breastfeeding women, or women planning to become pregnant during the study
  • Patients unwilling or unable to comply with the protocol
  • Otherwise located lower limb pain, such as hip pain

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

PHASE II

A teljes eredeti leírásKevesebb

- to assess the safety and tolerability of different escalating doses of IA clodronate in terms of serious adverse events (SAEs), adverse events (AEs), and abnormal laboratory or any clinical signs of intolerance. - to set the DTD to be used in Phase III, as the lowest clodronate dose leading to a ≥ 8.5 mm reduction in the VAS of knee pain at Week 7 vs. Placebo.

PHASE III

- to assess and confirm the therapeutic efficacy of DTD in patients with knee OA based on VAS score of knee pain at Week 7 vs. Placebo. - to assess the safety and tolerability of DTD in patients with knee OA in terms of SAEs, AEs, and abnormal laboratory or any clinical signs of intolerance.

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
A regiszteradat frissítve
2026. április 29.